Furui Medical forecasts profit decline despite revenue growth

Inner Mongolia Furui Medical Science expects net profit attributable to shareholders for the first half of 2025 to range from 50m to 60m yuan, a decrease of 20% to 34% compared to the previous year. Revenue is projected to grow by 11% to 16%, reaching approximately 470m to 490m yuan.

The profit decline is attributed to higher share-based payment expenses for equity incentives forecast at 12.4m yuan, up from 5.2m yuan previously. The company also expects a foreign exchange loss of approximately 15.2m yuan due to US dollar depreciation against the Euro, contrasting with an 8.6m yuan gain last year.